Madrigal Pharmaceuticals, Inc. (MDGL) Stock Score, Valuation & Financial Research

Madrigal Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MDGL

Madrigal Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 496.45. These figures are a research snapshot, not a buy or sell recommendation.

What Madrigal Pharmaceuticals, Inc. does

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Madrigal Pharmaceuticals is a biopharmaceutical company that generates revenue primarily through the commercialization and sale of its FDA-approved therapeutic, Rezdiffra. The company operates by developing and marketing novel liver-directed therapies for metabolic dysfunction-associated steatohepatitis (MASH), managing its own commercial infrastructure to reach specialized healthcare providers.

Products and services

  • Rezdiffra (resmetirom) is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist indicated for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis.

Brands and product families

  • Rezdiffra — The company's primary commercial product for the treatment of MASH. Source

Annual revenue by business

  • Reportable Segment: USD 958,403,000 · 100.00% calculated revenue share (period 2025-12-31) Source

Revenue share is not a unit-sales or best-seller ranking. Categories may overlap; do not add rows from different breakdowns.

Customer types

Specialty Pharmacies; Specialty Distributors.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of active pharmaceutical ingredients and finished drug products. Source

Business strengths to evaluate

  • First-mover advantage with FDA-approved therapy for MASH Source

Business risks and research considerations

  • Dependence on a single commercial product, Rezdiffra Source
  • Reliance on third-party manufacturers for supply chain Source

Sources: Company research source · Reportable Segment

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MDGL financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 496.45
Market capitalization:
11.47B (currency not supplied)
Revenue:
USD 1.28B
Net income:
USD -325.1M
Free cash flow:
USD -190.02M
Cash:
USD 292.73M
Total debt:
USD 347.75M
EPS:
USD -12.89

What stands out

  • Reported year-over-year revenue growth is +34.0%.
  • Free cash flow is USD -190.02M, negative for the stored period.
  • The balance sheet shows USD 292.73M of cash versus USD 347.75M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -14.8% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -25.3% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Debt exceeds cash by USD 55.03M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MDGL

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can MDGL sustain its current revenue growth while also converting that growth into durable profit and free cash flow?
  • How long can MDGL fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does MDGL's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for MDGL to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MDGL's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research MDGL

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.